Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
The company develops, manufactures, and markets pharmaceutical products in India, the United States, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology.
Glenmark Pharmaceuticals Limited, is a listed public company incorporated on 18 November, 1977. It is classified as a public limited company and is located in Mumbai, Maharashtra. It's authorized share capital is INR 277.00 cr and the total paid-up capital is INR 28.22 cr.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
0.97%
-12.76%
-39.49%
6.8%
-14.0%
7.29%
1.17
-2.82
-9.69
-5.18
-5.81
-0.04
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(43)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Bank of India
No. of Loans: 1
Total Amount : 890.0 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Blanche Saldanha Elizabeth
Shareholder
|
00007671 | 15 years |
| Director | Rajesh Vasudeo Desai
Shareholder
|
00007960 | 23 years |
| Managing Director | Glenn Mario Saldanha
Shareholder
|
00050607 | 26 years |
| Whole-time Director | Cherylann Maria Pinto
Shareholder
|
00111844 | 18 years |
| CFO | V S Mani
Shareholder
|
<HIDDEN> | 7 years |
| Whole-time Director | V S Mani
Shareholder
|
01082878 | 7 years |
| Director | Vijayalakshmi Iyer | 05242960 | 2 years |
| Director | Sona Saira Ramasastry | 08398547 | 6 years |
| Director | Dipankar Bhattacharjee | 08770548 | 4 years |
| CS | Harish Vinayak Kuber | <HIDDEN> | 8 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| GM PHARMA LIMITED |
Amalgamated
|
10.0 L | 2 | Maharashtra |
| GLENMARK ACCESS LIMITED |
Amalgamated
|
1.9 Cr | 3 | Maharashtra |
| GLENMARK GENERICS LIMITED |
Amalgamated
|
151.1 Cr | 2 | Maharashtra |
| DESVEN CONSULTANTS PRIVATE LIMITED |
Active
|
1.0 L | 1 | Maharashtra |
| QI LIFECARE PRIVATE LIMITED CN |
Active
|
4.0 Cr | 1 | Maharashtra |
| DORF-KETAL CHEMICALS INDIA LIMITED |
Active
|
246.8 Cr | 1 | Gujarat |
| GLENMARK HEALTHCARE LIMITED |
Active
|
9.1 Cr | 3 | Maharashtra |
| BFSI SECTOR SKILL COUNCIL OF INDIA |
Active
|
2.0 Cr | 1 | Maharashtra |
| COMPUTER AGE MANAGEMENT SERVICES LIMITED |
Active
|
49.2 Cr | 1 | Tamil Nadu |
| AXIS MUTUAL FUND TRUSTEE LIMITED |
Active
|
5.0 L | 1 | Maharashtra |
| GAWAR INVESTMENT MANAGER PRIVATE LIMITED |
Active
|
13.0 Cr | 1 | Haryana |
| AVANSE FINANCIAL SERVICES LIMITED |
Active
|
125.9 Cr | 1 | Maharashtra |
| L&T METRO RAIL (HYDERABAD) LIMITED |
Active
|
7,413.0 Cr | 1 | Telangana |
| ICICI SECURITIES LIMITED |
Active
|
162.0 Cr | 1 | Maharashtra |
| ADITYA BIRLA CAPITAL LIMITED |
Active
|
2,605.2 Cr | 1 | Gujarat |
| CG POWER AND INDUSTRIAL SOLUTIONS LIMITED |
Active
|
305.7 Cr | 1 | Maharashtra |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Glenmark Holding SA | Switzerland | - | - |
| Glenmark Pharmaceuticals S.A., Switzerland | Switzerland | - | - |
| Glenmark Farmaceutica Ltda. | Brazil | - | - |
| Glenmark Pharmaceutical SRO | Czech Republic | - | - |
| Glenmark Pharmaceutical SK SRO | Slovakia | - | - |
| Glenmark Pharmaceutical SRL | Romania | - | - |
| Glenmark Pharmaceuticals (Europe) R&D Ltd. | United Kingdom | - | - |
| Glenmark Therapeutics Inc., USA | United States | - | - |
| Glenmark Pharmaceuticals SP Z.O.O. | Poland | - | - |
| Glenmark-Pharmaceuticals Ecuador S.A. | Ecuador | - | - |
| Glenmark South Africa (pty) Ltd | South Africa | - | - |
| Glenmark Pharmaceuticals South Africa (pty) Ltd. | South Africa | - | - |
| Glenmark Impex L.L.C. | Russian Federation | - | - |
| Glenmark Pharmaceuticals (Nigeria) Ltd | Nigeria | - | - |
| Glenmark Dominicana SRL | Dominican Republic | - | - |
| Glenmark Pharmaceuticals (Australia) Pty Ltd. | Australia | - | - |
| Glenmark Pharmaceuticals (Malaysia) SDN.BHD | Malaysia | - | - |
| Glenmark Philippines Inc. | Philippines | - | - |
| Glenmark Pharmaceuticals Egypt SAE | Egypt | - | - |
| Glenmark Pharmaceuticals FZE | United Arab Emirates | - | - |
| Glenmark Uruguay SA | Uruguay | - | - |
| Glenmark Pharmaceuticals Mexico, S.A DECV. | Mexico | - | - |
| Glenmark Pharmaceuticals Peru SAC. | Peru | - | - |
| Glenmark Pharmaceuticals Venezuela , CA | Venezuela, Bolivarian Republic Of | - | - |
| Glenmark Pharmaceuticals Colombia SAS | Colombia | - | - |
| Glenmark Pharmaceuticals Europe Ltd. | United Kingdom | - | - |
| Glenmark Pharmaceuticals Inc. USA | United States | - | - |
| Glenmark Generics SA Argentina | Argentina | - | - |
| Glenmark Pharmaceuticals B.V. | Netherlands | - | - |
| Glenmark Arzneimittel GmBH | Germany | - | - |
| Glenmark Pharmaceuticals Canada INC | Canada | - | - |
| Glenmark Pharmaceuticals (Kenya) Limited | Kenya | - | - |
| Glenmark Ttherapeutics AG | Switzerland | - | - |
| Glenmark Pharmaceuticals Distribution SRO | Czech Republic | - | - |
| Glenmark Specialty SA | Switzerland | - | - |
| Viso Farmaceutica SLU | Spain | - | - |
| Glenmark Pharmaceuticals (Thailand) Co. Ltd. | Thailand | - | - |
| Glenmark Pharmaceuticals Nordic AB | Sweden | - | - |
| Glenmark Ukraine LLC | Ukraine | - | - |
The incorporation date of GLENMARK PHARMACEUTICALS LIMITED is 18 November, 1977
The authorized share capital of GLENMARK PHARMACEUTICALS LIMITED is INR ₹ 277.0 Cr.
The paid-up capital of GLENMARK PHARMACEUTICALS LIMITED is INR ₹ 28.2 Cr.
The registered address of GLENMARK PHARMACEUTICALS LIMITED is B-2MAHALAXMI CHAMBERS22 BHULABHAI DESAI ROAD MAHALAXMI NA MUMBAI Maharashtra - 400026
The CIN number of GLENMARK PHARMACEUTICALS LIMITED is L24299MH1977PLC019982.
Expand
Delete
Collapse
See
details
